statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexaria receives new patents in the fields of epilepsy and anti-viral agentsKELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or...

Lexaria Awarded New Patents

Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms...

Lexaria to Present at The LD Micro Invitational XIV

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lexaria Bioscience appoints Nelson Cabatuan as CFO

KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms announces the appointment...

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience files to sell 1.61M shares of common stock for holders...

Lexaria Bioscience files to sell 1.61M shares of common stock for holders

Lexaria Bioscience Corp. (LEXX) has released an update. Lexaria Bioscience Corp. has embarked on its second human pilot study using its proprietary...

Lexaria Bioscience Advances Oral Diabetes Treatment

First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be testedRybelsus(R) semaglutide will act as the positive controlKELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp...

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Lexaria Bioscience price target raised by $9 at Maxim, here's why

Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be testedChronic dosing over a 12-week treatment periodWill assess weight loss and blood glucose level controlEfficacy through possible...

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

KELOWNA, BC / ACCESSWIRE / March 4, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, informs that its...

7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Volume	47,380.00
52-Wk High	$6.85
52-Wk Low	$0.6488

LEXX Lexaria Bioscience Corp

About

Feed

News

Fundamentals